Hexaminolevulinate Guided Fluorescence Cystoscopy Reduces Recurrence in Patients with Nonmuscle Invasive Bladder Cancer

Overview

Journal J Urol

Publisher Wolters Kluwer

Specialty Urology

Date 2010 Sep 21

PMID 20850152

Citations 81

Authors

Arnulf Stenzl

Maximilian Burger

Yves Fradet

Lance A Mynderse

Mark S Soloway

J Alfred Witjes

Martin Kriegmair

Alexander Karl

Yu Shen

H Barton Grossman

Affiliations

Soon will be listed here.

Abstract

Purpose: We assessed the impact that improved detection of nonmuscle invasive bladder cancer with hexaminolevulinate fluorescence cystoscopy may have on early recurrence rates.

Materials And Methods: This prospective, randomized study enrolled 814 patients suspected of having bladder cancer at increased risk for recurrence. All patients underwent white light cystoscopy and mapping of lesions, followed by transurethral resection of the bladder when indicated. Patients in the fluorescence group also received intravesical hexaminolevulinate solution at least 1 hour before cystoscopy to induce fluorescence of cancerous lesions, and underwent additional inspection with blue light before and after transurethral resection of the bladder. Adjuvant intravesical therapy was based on risk. Followup cystoscopy at 3, 6 and 9 months was conducted with white light.

Results: Detection was performed as a within patient comparison in the fluorescence group. In this group 286 patients had at least 1 Ta or T1 tumor (intent to treat). In 47 patients (16%) at least 1 of the tumors was seen only with fluorescence (p = 0.001). During the 9-month followup (intent to treat) there was tumor recurrence in 128 of 271 patients (47%) in the fluorescence group and 157 of 280 (56%) in the white light group (p = 0.026). The relative reduction in recurrence rate was 16%.

Conclusions: Hexaminolevulinate fluorescence cystoscopy significantly improves the detection of Ta and T1 lesions and significantly reduces the rate of tumor recurrence at 9 months.

Citing Articles

Electrical impedance-based tissue classification for bladder tumor differentiation.

Veil C, Krauss F, Amend B, Fend F, Sawodny O Sci Rep. 2025; 15(1):825.

PMID: 39755796 PMC: 11700109. DOI: 10.1038/s41598-024-84844-9.

The Management of Non-Muscle-Invasive Bladder Cancer in a Veteran Patient Population: Issues and Recommendations.

Taylor J, Patel S, Gaitonde K, Greene K, Liao J, McWilliams G Curr Oncol. 2024; 31(11):6686-6698.

PMID: 39590124 PMC: 11592542. DOI: 10.3390/curroncol31110493.

Economic Outcomes of Hexaminolevulinate Blue-Light Cystoscopy in Non-Muscle Invasive Bladder Cancer: A 5-Year, Medicare-Based Model.

Creswell M, Sholklapper T, Markel M, Mason J, Pianka M, Dall C Bladder Cancer. 2024; 9(1):87-96.

PMID: 38994485 PMC: 11181828. DOI: 10.3233/BLC-220027.

Perioperative Outcomes and Trends in Transurethral Resection of Bladder Tumors with Photodynamic Diagnosis: Results from the GeRmAn Nationwide Inpatient Data Study.

Pyrgidis N, Moschini M, Tzelves L, Somani B, Juliebo-Jones P, Del Giudice F J Clin Med. 2024; 13(12).

PMID: 38930060 PMC: 11204857. DOI: 10.3390/jcm13123531.

Intraoperative fluorescence redefining neurosurgical precision.

Regmi M, Li Y, Wang Y, Liu W, Dai Y, Liu S Int J Surg. 2024; 111(1):998-1013.

PMID: 38913424 PMC: 11745677. DOI: 10.1097/JS9.0000000000001847.

References

Botteman M, Pashos C, Redaelli A, Laskin B, Hauser R . The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2004; 21(18):1315-30. DOI: 10.1007/BF03262330. View

Jakse G, Algaba F, Malmstrom P, Oosterlinck W . A second-look TUR in T1 transitional cell carcinoma: why?. Eur Urol. 2004; 45(5):539-46. DOI: 10.1016/j.eururo.2003.12.016. View

Epstein J, Amin M, Reuter V, Mostofi F . The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998; 22(12):1435-48. DOI: 10.1097/00000478-199812000-00001. View

Schroder F, Hugosson J, Roobol M, Tammela T, Ciatto S, Nelen V . Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360(13):1320-8. DOI: 10.1056/NEJMoa0810084. View

Klan R, Loy V, Huland H . Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol. 1991; 146(2):316-8. DOI: 10.1016/s0022-5347(17)37779-0. View

Geavlete B, Multescu R, Georgescu D, Geavlete P . Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors. J Endourol. 2009; 23(6):977-81. DOI: 10.1089/end.2008.0574. View

Babjuk M, Soukup V, Petrik R, Jirsa M, Dvoracek J . 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int. 2005; 96(6):798-802. DOI: 10.1111/j.1464-410X.2004.05715.x. View

Jichlinski P, Forrer M, Mizeret J, Glanzmann T, Braichotte D, Wagnieres G . Clinical evaluation of a method for detecting superficial surgical transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following the topical application of 5-aminolevulinic acid: preliminary results. Lasers Surg Med. 1997; 20(4):402-8. DOI: 10.1002/(sici)1096-9101(1997)20:4<402::aid-lsm5>3.0.co;2-u. View

Sievert K, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M . Economic aspects of bladder cancer: what are the benefits and costs?. World J Urol. 2009; 27(3):295-300. PMC: 2694315. DOI: 10.1007/s00345-009-0395-z. View

10.

Denzinger S, Burger M, Walter B, Knuechel R, Roessler W, Wieland W . Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology. 2007; 69(4):675-9. DOI: 10.1016/j.urology.2006.12.023. View

11.

Burger M, Zaak D, Stief C, Filbeck T, Wieland W, Roessler W . Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol. 2007; 52(1):142-7. DOI: 10.1016/j.eururo.2007.01.064. View

12.

Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M . Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol. 2003; 171(1):135-8. DOI: 10.1097/01.ju.0000100480.70769.0e. View

13.

McKenney J, Gomez J, Desai S, Lee M, Amin M . Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol. 2001; 25(3):356-62. DOI: 10.1097/00000478-200103000-00010. View

14.

Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, Grimm M . Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol. 2005; 174(3):862-6. DOI: 10.1097/01.ju.0000169257.19841.2a. View

15.

Marchetti A, Wang L, Magar R, Grossman H, Lamm D, Schellhammer P . Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. Clin Ther. 2000; 22(4):422-38. DOI: 10.1016/s0149-2918(00)89011-6. View

16.

Krieg R, Messmann H, Rauch J, Seeger S, Knuechel R . Metabolic characterization of tumor cell-specific protoporphyrin IX accumulation after exposure to 5-aminolevulinic acid in human colonic cells. Photochem Photobiol. 2002; 76(5):518-25. DOI: 10.1562/0031-8655(2002)076<0518:mcotcs>2.0.co;2. View

17.

Daniltchenko D, Riedl C, Sachs M, Koenig F, Daha K, Pflueger H . Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol. 2005; 174(6):2129-33, discussion 2133. DOI: 10.1097/01.ju.0000181814.73466.14. View

18.

Schumacher M, Holmang S, Davidsson T, Friedrich B, Pedersen J, Wiklund N . Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol. 2009; 57(2):293-9. DOI: 10.1016/j.eururo.2009.10.030. View

19.

Grossman H, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C . A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol. 2007; 178(1):62-7. DOI: 10.1016/j.juro.2007.03.034. View

20.

Kennedy J, Pottier R, Pross D . Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B. 1990; 6(1-2):143-8. DOI: 10.1016/1011-1344(90)85083-9. View